Skip to Content

Join the 'Donepezil' group to help and get support from people like you.

Donepezil News

Dementia Meds May Lead to Harmful Weight Loss: Study

Posted 3 Aug 2015 by Drugs.com

MONDAY, Aug. 3, 2015 – A class of drugs widely used to treat dementia – called cholinesterase inhibitors – could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead author Dr. Meera Sheffrin, a geriatrics fellow in the School of Medicine, at the University of California, San Francisco, said in a university news release. One expert said the findings point out a common problem for Alzheimer's patients. "Weight loss is a concern, not only for patients but also for their overwhelmed caregivers, who keep struggling with multiple challenges, including providing their ... Read more

Related support groups: Weight Loss, Dementia, Alzheimer's Disease, Aricept, Donepezil, Exelon, Mild Cognitive Impairment, Rivastigmine, Arteriosclerotic Dementia, Galantamine, Reminyl, Cachexia, Razadyne, Razadyne ER, Tacrine, Cognex, Namzaric, Aricept ODT, Lewy Body Dementia, Donepezil/memantine

Alzheimer's Drugs May Benefit Heart, Study Finds

Posted 5 Jun 2013 by Drugs.com

WEDNESDAY, June 5 – Drugs used to treat early-stage Alzheimer's disease may also reduce patients' risk of heart attack and death, according to a new study. Researchers followed more than 7,000 Alzheimer's disease patients in Sweden for more than three years. Those taking cholinesterase inhibitors had a 38 percent lower risk of heart attack, a 26 percent lower risk of death from cardiovascular causes such as stroke and a 36 percent lower risk of death from any cause, compared to those who did not take the drugs. Patients who took the highest recommended doses of cholinesterase inhibitors (ChEIs) had the lowest risk of heart attack or death – 65 percent and 46 percent lower, respectively, than those who never took the drugs, according to the study, which was published online June 5 in the European Heart Journal. "If you translate these reductions in risk into absolute figures, it means ... Read more

Related support groups: Heart Attack, Alzheimer's Disease, Aricept, Myocardial Infarction, Donepezil, Exelon, Cardiovascular Risk Reduction, Rivastigmine, Galantamine, Reminyl, Razadyne, Razadyne ER, Aricept ODT

Study Produces Mixed Results on Alzheimer's Drugs

Posted 7 Mar 2012 by Drugs.com

WEDNESDAY, March 7 – A new study offers up mixed results about two medications used to treat the symptoms of the memory-robbing disease known as Alzheimer's. While patients didn't get a major mental boost when doctors added the drug Namenda to their regimen when they were already taking Aricept, they did find that continuing Aricept – a commonly prescribed drug for Alzheimer's in the United States – seemed to help. The results, which appear in the March 8 issue of the New England Journal of Medicine, may seem a bit murky, especially because it's difficult to measure the effects of the drugs on day-to-day living. However, study author Dr. Robert Howard, a professor of old age psychiatry and psychopathology at the Institute of Psychiatry at King's College London, said both drugs are worth taking, possibly even together. "While these drugs will not stop or slow down the tragic course of ... Read more

Related support groups: Alzheimer's Disease, Namenda, Aricept, Donepezil, Namenda XR, Memantine, Aricept ODT

Some People With Alzheimer's Take Conflicting Drugs

Posted 28 Oct 2011 by Drugs.com

FRIDAY, Oct. 28 – Many Alzheimer's patients who take cholinesterase inhibitors to slow their brain disease also take drugs that counter the effects of those Alzheimer's medications, a new study says. Clinical trials have shown that cholinesterase inhibitors such as Aricept (donepezil) have a modest impact on the functional and cognitive decline caused by Alzheimer's disease, noted the researchers at the Group Health Research Institute in Seattle. "Cholinesterase inhibitors are today's primary therapy for slowing Alzheimer's disease," study leader Denise Boudreau said in an institute news release. "Anticholinergic properties are often found in drugs commonly used to treat gastrointestinal disorders, allergies, urinary incontinence, depression and Parkinson's disease, and they can have negative effects on cognition and function in the elderly. There's concern that if someone is taking ... Read more

Related support groups: Benadryl, Alzheimer's Disease, Diphenhydramine, Oxybutynin, Meclizine, Aricept, Dramamine, Donepezil, Ditropan, Oxytrol, Cogentin, Exelon, Benztropine, Scopolamine, Benadryl Allergy, Antivert, Artane, Bonine, Transderm-Scop, Rivastigmine

Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer's Disease

Posted 26 Jul 2010 by Drugs.com

WOODCLIFF LAKE, N.J. & NEW YORK--(BUSINESS WIRE)--Jul 24, 2010 - Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer's disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are available. According to the Alzheimer's Association, approximately 3.6 million Americans age 65 and older have moderate-to-severe AD. The approval of Aricept 23 mg tablet is based on data from a large head-to-head study of Aricept 23 mg tablet versus Aricept 10 mg tablet in over 1,400 patients with moderate-to-severe AD. Two co-primary endpoints were examined: the Severe Impairment Battery (SIB), a validated clinical instrument that measures cognition, and the Clinician's ... Read more

Related support groups: Alzheimer's Disease, Donepezil

FDA Approves Generic Aricept to Treat Dementia Related to Alzheimer's Disease

Posted 16 Dec 2009 by Drugs.com

ROCKVILLE, Md., Dec. 16, 2009-The U.S. Food and Drug Administration approved the first generic versions of Aricept (donepezil hydrochloride) orally disintegrating tablets on Dec. 11. Donepezil hydrochloride is indicated for the treatment of dementia related to Alzheimer's disease. Orally disintegrating tablets dissolve on the tongue, without having to be swallowed whole. This may make it easier to take the medication for older or disabled patients who have difficulty swallowing. "Generics offer greater access to health care for all Americans," said Gary Buehler, director of the FDA's Office of Generic Drugs. "Health care professionals and consumers can be assured that FDA-approved generic drugs have met the same rigorous standards as the brand-name drug and are the same as the branded in dosage form, safety, strength, route of administration, quality, performance characteristics and ... Read more

Related support groups: Aricept, Donepezil, Aricept ODT

Ask a Question

Further Information

Related Condition Support Groups

Mild Cognitive Impairment, Alzheimer's Disease, Lewy Body Dementia

Related Drug Support Groups

Aricept, Aricept ODT

Donepezil Patient Information at Drugs.com